TESC Promotes TGF-α/EGFR-FOXM1-Mediated Tumor Progression in Cholangiocarcinoma
Abstract
1. Introduction
2. Results
2.1. Identification of Genes Upregulated and Associated with Overall Survival (OS) in Cholangiocarcinoma
2.2. Participation of TESC in Cholangiocarcinoma
2.3. TESC Regulates G2/M Phase Through FOXM1
2.4. TESC Is Induced by TGF-α/STAT3 Signaling
2.5. TESC Enhances TGF-α-Induced Cell Proliferation Via FOXM1
2.6. TESC Mediates ICC Tumor Growth In Vivo
3. Discussion
4. Materials and Methods
4.1. Reagents
4.2. Cell Culture
4.3. Reverse Transcription-Quantitative PCR
4.4. MTT Assay
4.5. Clonogenic Assay
4.6. Luciferase Reporter Assay
4.7. Chromatin Immunoprecipitation (ChIP)
4.8. Co-Immunoprecipitation Assay and Immunoblotting
4.9. Plasmid Construction
4.10. Xenograft Tumorigenicity Assay
4.11. Immunohistochemistry
4.12. Cell Cycle Analysis
4.13. Wound Healing Assay
4.14. Patients and Tissue Samples
4.15. Next-Generation Sequencing and Data Analysis
4.16. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Alvaro, D. The challenge of cholangiocarcinoma diagnosis: The turning point is in extracellular vesicles? Hepatology 2017, 66, 1029–1031. [Google Scholar] [CrossRef]
- Park, H.M.; Yun, S.P.; Lee, E.C.; Lee, S.D.; Han, S.S.; Kim, S.H.; Park, S.J. Outcomes for Patients with Recurrent Intrahepatic Cholangiocarcinoma After Surgery. Ann. Surg. Oncol. 2016, 23, 4392–4400. [Google Scholar] [CrossRef] [PubMed]
- Lewis, H.L.; Rahnemai-Azar, A.A.; Dillhoff, M.; Schmidt, C.R.; Pawlik, T.M. Current Management of Perihilar Cholangiocarcinoma and Future Perspectives. Chirurgia (Bucur) 2017, 112, 193–207. [Google Scholar] [CrossRef] [PubMed]
- Tsukamoto, M.; Yamashita, Y.I.; Imai, K.; Umezaki, N.; Yamao, T.; Okabe, H.; Nakagawa, S.; Hashimoto, D.; Chikamoto, A.; Ishiko, T.; et al. Predictors of Cure of Intrahepatic Cholangiocarcinoma after Hepatic Resection. Anticancer Res. 2017, 37, 6971–6975. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Bridgewater, J.; Galle, P.R.; Khan, S.A.; Llovet, J.M.; Park, J.W.; Patel, T.; Pawlik, T.M.; Gores, G.J. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J. Hepatol. 2014, 60, 1268–1289. [Google Scholar] [CrossRef]
- Perera, E.M.; Martin, H.; Seeherunvong, T.; Kos, L.; Hughes, I.A.; Hawkins, J.R.; Berkovitz, G.D. Tescalcin, a Novel Gene Encoding a Putative EF-Hand Ca2+-Binding Protein, Col9a3, and Renin Are Expressed in the Mouse Testis during the Early Stages of Gonadal Differentiation. Endocrinology 2001, 142, 455–463. [Google Scholar] [CrossRef]
- Mailänder, J.; Müller-Esterl, W.; Dedio, J. Human homolog of mouse tescalcin associates with Na+/H+ exchanger type-1. FEBS Lett. 2001, 507, 331–335. [Google Scholar] [CrossRef]
- Li, X.; Liu, Y.; Kay, C.M.; Müller-Esterl, W.; Fliegel, L. The Na+/H+ Exchanger Cytoplasmic Tail: Structure, Function, and Interactions with Tescalcin. Biochemistry 2003, 42, 7448–7456. [Google Scholar] [CrossRef]
- Levay, K.; Slepak, V.Z. Tescalcin is an essential factor in megakaryocytic differentiation associated with Ets family gene expression. J. Clin. Investig. 2007, 117, 2672–2683. [Google Scholar] [CrossRef]
- Port, M.; Boltze, C.; Wang, Y.; Roper, B.; Meineke, V.; Abend, M. A radiation-induced gene signature distinguishes post-Chernobyl from sporadic papillary thyroid cancers. Radiat. Res. 2007, 168, 639–649. [Google Scholar] [CrossRef]
- Stein, L.; Rothschild, J.; Luce, J.; Cowell, J.K.; Thomas, G.; Bogdanova, T.I.; Tronko, M.D.; Hawthorn, L. Copy Number and Gene Expression Alterations in Radiation-Induced Papillary Thyroid Carcinoma from Chernobyl Pediatric Patients. Thyroid 2009, 20, 475–487. [Google Scholar] [CrossRef] [PubMed]
- Kang, Y.H.; Han, S.R.; Kim, J.T.; Lee, S.J.; Yeom, Y.I.; Min, J.K.; Lee, C.H.; Kim, J.W.; Yoon, S.R.; Yoon, D.Y.; et al. The EF-hand calcium-binding protein tescalcin is a potential oncotarget in colorectal cancer. Oncotarget 2014, 5, 2149–2160. [Google Scholar] [CrossRef] [PubMed]
- Kang, J.; Kang, Y.H.; Oh, B.M.; Uhm, T.G.; Park, S.Y.; Kim, T.W.; Han, S.R.; Lee, S.J.; Lee, Y.; Lee, H.G. Tescalcin expression contributes to invasive and metastatic activity in colorectal cancer. Tumour Biol. 2016, 37, 13843–13853. [Google Scholar] [CrossRef] [PubMed]
- Luo, A.J.; Tan, J.; He, L.Y.; Jiang, X.Z.; Jiang, Z.Q.; Zeng, Q.; Yao, K.; Xue, J. Suppression of Tescalcin inhibits growth and metastasis in renal cell carcinoma via downregulating NHE1 and NF-kB signaling. Exp. Mol. Pathol. 2019, 107, 110–117. [Google Scholar] [CrossRef]
- Dictor, M.; Ehinger, M.; Mertens, F.; Akervall, J.; Wennerberg, J. Abnormal cell cycle regulation in malignancy. Am. J. Clin. Pathol. 1999, 112, S40–S52. [Google Scholar]
- Sherr, C.J. Cancer cell cycles. Science 1996, 274, 1672–1677. [Google Scholar] [CrossRef]
- Leung, T.W.C.; Lin, S.S.W.; Tsang, A.C.C.; Tong, C.S.W.; Ching, J.C.Y.; Leung, W.Y.; Gimlich, R.; Wong, G.G.; Yao, K.-M. Over-expression of FoxM1 stimulates cyclin B1 expression. FEBS Lett. 2001, 507, 59–66. [Google Scholar] [CrossRef]
- Laoukili, J.; Kooistra, M.R.; Bras, A.; Kauw, J.; Kerkhoven, R.M.; Morrison, A.; Clevers, H.; Medema, R.H. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat. Cell Biol. 2005, 7, 126–136. [Google Scholar] [CrossRef]
- Wang, I.C.; Chen, Y.-J.; Hughes, D.; Petrovic, V.; Major, M.L.; Park, H.J.; Tan, Y.; Ackerson, T.; Costa, R.H. Forkhead Box M1 Regulates the Transcriptional Network of Genes Essential for Mitotic Progression and Genes Encoding the SCF (Skp2-Cks1) Ubiquitin Ligase. Mol. Cell. Biol. 2005, 25, 10875–10894. [Google Scholar] [CrossRef]
- Park, H.J.; Costa, R.H.; Lau, L.F.; Tyner, A.L.; Raychaudhuri, P. Anaphase-Promoting Complex/Cyclosome-Cdh1-Mediated Proteolysis of the Forkhead Box M1 Transcription Factor Is Critical for Regulated Entry into S Phase. Mol. Cell. Biol. 2008, 28, 5162–5171. [Google Scholar] [CrossRef]
- Xu, X.S.; Miao, R.C.; Wan, Y.; Zhang, L.Q.; Qu, K.; Liu, C. FoxM1 as a novel therapeutic target for cancer drug therapy. APJCP 2015, 16, 23–29. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Yang, Y.S.H.; Chang, H.W.; Lin, I.H.; Chien, L.N.; Wu, M.J.; Liu, Y.R.; Chu, P.G.; Xie, G.; Dong, F.; Jia, W.; et al. Long-term Proton Pump Inhibitor Administration Caused Physiological and Microbiota Changes in Rats. Sci. Rep. 2020, 10, 866. [Google Scholar] [CrossRef] [PubMed]
- Werneburg, N.W.; Yoon, J.-H.; Higuchi, H.; Gores, G.J. Bile acids activate EGF receptor via a TGF-α-dependent mechanism in human cholangiocyte cell lines. Am. J. Physiol.-Gastrointest. Liver Physiol. 2003, 285, G31–G36. [Google Scholar] [CrossRef] [PubMed]
- Zhang, C.; Xu, H.; Zhou, Z.; Tian, Y.; Cao, X.; Cheng, G.; Liu, Q. Blocking of the EGFR-STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma. Exp. Ther. Med. 2018, 15, 4995–5000. [Google Scholar] [CrossRef]
- Stoll, S.W.; Stuart, P.E.; Swindell, W.R.; Tsoi, L.C.; Li, B.; Gandarillas, A.; Lambert, S.; Johnston, A.; Nair, R.P.; Elder, J.T. The EGF receptor ligand amphiregulin controls cell division via FoxM1. Oncogene 2016, 35, 2075–2086. [Google Scholar] [CrossRef]
- Chang-Panesso, M.; Kadyrov, F.F.; Lalli, M.; Wu, H.; Ikeda, S.; Kefaloyianni, E.; Abdelmageed, M.M.; Herrlich, A.; Kobayashi, A.; Humphreys, B.D. FOXM1 drives proximal tubule proliferation during repair from acute ischemic kidney injury. J. Clin. Investig. 2019, 129, 5501–5517. [Google Scholar] [CrossRef]
- Di Sole, F.; Vadnagara, K.; Moe, O.W.; Babich, V. Calcineurin homologous protein: A multifunctional Ca2+-binding protein family. Am. J. Physiol. Renal Physiol. 2012, 303, F165–F179. [Google Scholar] [CrossRef]
- Kolobynina, K.G.; Solovyova, V.V.; Levay, K.; Rizvanov, A.A.; Slepak, V.Z. Emerging roles of the single EF-hand Ca2+ sensor tescalcin in the regulation of gene expression, cell growth and differentiation. J. Cell Sci. 2016, 129, 3533–3540. [Google Scholar] [CrossRef]
- Barroso, M.R.; Bernd, K.K.; DeWitt, N.D.; Chang, A.; Mills, K.; Sztul, E.S. A novel Ca2+-binding protein, p22, is required for constitutive membrane traffic. J. Biol. Chem. 1996, 271, 10183–10187. [Google Scholar] [CrossRef]
- Lin, X.; Barber, D.L. A calcineurin homologous protein inhibits GTPase-stimulated Na-H exchange. Proc. Natl. Acad. Sci. USA 1996, 93, 12631–12636. [Google Scholar] [CrossRef]
- Inoue, H.; Nakamura, Y.; Nagita, M.; Takai, T.; Masuda, M.; Nakamura, N.; Kanazawa, H. Calcineurin homologous protein isoform 2 (CHP2), Na+/H+ exchangers-binding protein, is expressed in intestinal epithelium. Biol. Pharm. Bull. 2003, 26, 148–155. [Google Scholar] [CrossRef] [PubMed]
- Li, G.D.; Zhang, X.; Li, R.; Wang, Y.D.; Wang, Y.L.; Han, K.J.; Qian, X.P.; Yang, C.G.; Liu, P.; Wei, Q.; et al. CHP2 activates the calcineurin/nuclear factor of activated T cells signaling pathway and enhances the oncogenic potential of HEK293 cells. J. Biol. Chem. 2008, 283, 32660–32668. [Google Scholar] [CrossRef]
- Pang, T.; Wakabayashi, S.; Shigekawa, M. Expression of calcineurin B homologous protein 2 protects serum deprivation-induced cell death by serum-independent activation of Na+/H+ exchanger. J. Biol. Chem. 2002, 277, 43771–43777. [Google Scholar] [CrossRef] [PubMed]
- Jin, Q.; Kong, B.; Yang, X.; Cui, B.; Wei, Y.; Yang, Q. Overexpression of CHP2 enhances tumor cell growth, invasion and metastasis in ovarian cancer. In Vivo 2007, 21, 593–598. [Google Scholar] [PubMed]
- Hammam, A.A.; Eissa, H.H.; El Masry, M.R.; Mahmoud, S. CHP2 gene expression and quantitation in Egyptian patients with acute leukemia. Meta Gene 2014, 2, 323–331. [Google Scholar] [CrossRef]
- Clapham, D.E. Calcium signaling. Cell 2007, 131, 1047–1058. [Google Scholar] [CrossRef]
- Zhou, Y.; Xue, S.; Yang, J.J. Calciomics: Integrative studies of Ca2+-binding proteins and their interactomes in biological systems. Metall. Integr. Biometal Sci. 2013, 5, 29–42. [Google Scholar] [CrossRef]
- Ukarapong, S.; Bao, Y.; Perera, E.M.; Berkovitz, G.D. Megakaryocyte development is normal in mice with targeted disruption of Tescalcin. Exp. Cell Res. 2012, 318, 662–669. [Google Scholar] [CrossRef]
- Fan, J.; Xing, Y.; Wen, X.; Jia, R.; Ni, H.; He, J.; Ding, X.; Pan, H.; Qian, G.; Ge, S.; et al. Long non-coding RNA ROR decoys gene-specific histone methylation to promote tumorigenesis. Genome Biol. 2015, 16, 139. [Google Scholar] [CrossRef]
- Yoon, J.H.; Gwak, G.Y.; Lee, H.S.; Bronk, S.F.; Werneburg, N.W.; Gores, G.J. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J. Hepatol. 2004, 41, 808–814. [Google Scholar] [CrossRef]
- Yoshikawa, D.; Ojima, H.; Iwasaki, M.; Hiraoka, N.; Kosuge, T.; Kasai, S.; Hirohashi, S.; Shibata, T. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br. J. Cancer 2008, 98, 418–425. [Google Scholar] [CrossRef] [PubMed]
- Lee, J.H.; Choi, S.I.; Kim, R.K.; Cho, E.W.; Kim, I.G. Tescalcin/c-Src/IGF1Rbeta-mediated STAT3 activation enhances cancer stemness and radioresistant properties through ALDH1. Sci. Rep. 2018, 8, 10711. [Google Scholar] [CrossRef] [PubMed]
- Lee, J.; Park, S.H.; Chang, H.M.; Kim, J.S.; Choi, H.J.; Lee, M.A.; Jang, J.S.; Jeung, H.C.; Kang, J.H.; Lee, H.W.; et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012, 13, 181–188. [Google Scholar] [CrossRef]
- Hsieh, C.H.; Chou, Y.T.; Kuo, M.H.; Tsai, H.P.; Chang, J.L.; Wu, C.W. A targetable HB-EGF-CITED4 axis controls oncogenesis in lung cancer. Oncogene 2017, 36, 2946–2956. [Google Scholar] [CrossRef]
- Chou, Y.T.; Lee, C.C.; Hsiao, S.H.; Lin, S.E.; Lin, S.C.; Chung, C.H.; Chung, C.H.; Kao, Y.R.; Wang, Y.H.; Chen, C.T.; et al. The emerging role of SOX2 in cell proliferation and survival and its crosstalk with oncogenic signaling in lung cancer. Stem Cells 2013, 31, 2607–2619. [Google Scholar] [CrossRef]
- Chou, Y.T.; Lin, H.H.; Lien, Y.C.; Wang, Y.H.; Hong, C.F.; Kao, Y.R.; Lin, S.C.; Chang, Y.C.; Lin, S.Y.; Chen, S.J.; et al. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res. 2010, 70, 8822–8831. [Google Scholar] [CrossRef]
- Chou, Y.T.; Hsieh, C.H.; Chiou, S.H.; Hsu, C.F.; Kao, Y.R.; Lee, C.C.; Chung, C.H.; Wang, Y.H.; Hsu, H.S.; Pang, S.T.; et al. CITED2 functions as a molecular switch of cytokine-induced proliferation and quiescence. Cell Death Differ. 2012, 19, 2015–2028. [Google Scholar] [CrossRef]
- Oishi, N.; Kumar, M.R.; Roessler, S.; Ji, J.; Forgues, M.; Budhu, A.; Zhao, X.; Andersen, J.B.; Ye, Q.H.; Jia, H.L.; et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology 2012, 56, 1792–1803. [Google Scholar] [CrossRef]
- Chaisaingmongkol, J.; Budhu, A.; Dang, H.; Rabibhadana, S.; Pupacdi, B.; Kwon, S.M.; Forgues, M.; Pomyen, Y.; Bhudhisawasdi, V.; Lertprasertsuke, N.; et al. Common Molecular Subtypes among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. Cancer Cell 2017, 32, 57–70 e53. [Google Scholar] [CrossRef]
- Murakami, Y.; Kubo, S.; Tamori, A.; Itami, S.; Kawamura, E.; Iwaisako, K.; Ikeda, K.; Kawada, N.; Ochiya, T.; Taguchi, Y.H. Comprehensive analysis of transcriptome and metabolome analysis in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Sci. Rep. 2015, 5, 16294. [Google Scholar] [CrossRef]
- Kim, D.; Langmead, B.; Salzberg, S.L. HISAT: A fast spliced aligner with low memory requirements. Nat. Methods 2015, 12, 357–360. [Google Scholar] [CrossRef] [PubMed]
- Pertea, M.; Kim, D.; Pertea, G.M.; Leek, J.T.; Salzberg, S.L. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat. Protoc. 2016, 11, 1650–1667. [Google Scholar] [CrossRef] [PubMed]
- Liao, Y.; Smyth, G.K.; Shi, W. featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 2014, 30, 923–930. [Google Scholar] [CrossRef] [PubMed]
- GSEA. Available online: http://www.broadinstitute.org/gsea (accessed on 20 May 2019).
- ConsensusPathDB. Available online: http://cpdb.molgen.mpg.de (accessed on 15 May 2019).
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hsieh, C.-H.; Chu, C.-Y.; Lin, S.-E.; Yang, Y.-C.S.H.; Chang, H.-S.; Yen, Y. TESC Promotes TGF-α/EGFR-FOXM1-Mediated Tumor Progression in Cholangiocarcinoma. Cancers 2020, 12, 1105. https://doi.org/10.3390/cancers12051105
Hsieh C-H, Chu C-Y, Lin S-E, Yang Y-CSH, Chang H-S, Yen Y. TESC Promotes TGF-α/EGFR-FOXM1-Mediated Tumor Progression in Cholangiocarcinoma. Cancers. 2020; 12(5):1105. https://doi.org/10.3390/cancers12051105
Chicago/Turabian StyleHsieh, Cheng-Han, Cheng-Ying Chu, Sey-En Lin, Yu-Chen S.H. Yang, Hung-Shu Chang, and Yun Yen. 2020. "TESC Promotes TGF-α/EGFR-FOXM1-Mediated Tumor Progression in Cholangiocarcinoma" Cancers 12, no. 5: 1105. https://doi.org/10.3390/cancers12051105
APA StyleHsieh, C.-H., Chu, C.-Y., Lin, S.-E., Yang, Y.-C. S. H., Chang, H.-S., & Yen, Y. (2020). TESC Promotes TGF-α/EGFR-FOXM1-Mediated Tumor Progression in Cholangiocarcinoma. Cancers, 12(5), 1105. https://doi.org/10.3390/cancers12051105